AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 91 min read$IONS

BENNETT C FRANK sold $1.3M of IONS (indirect holdings)

BENNETT C FRANK (EVP, Chief Scientific Officer) sold 15,000 indirectly-held shares of IONIS PHARMACEUTICALS INC (IONS) at $85.46 ($1.28M total) on 2026-07-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · BENNETT C FRANK
Published Jul 9, 2026, 11:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 9, 2026, 11:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$IONS
Neutral
high confidence
Mentioned
$IONS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IONSNeutralLow
01

Why it matters

The only new information is the size, price, and timing of the insider sale; it does not include any new clinical, regulatory, or financial datapoints.

02

Market read

Traders may monitor insider activity, but this specific disclosure is unlikely to drive a material repricing without additional company-specific catalysts.

03

What to watch

The transaction is explicitly pre-arranged and the holdings after the transaction are 0 shares, which can reflect diversification or scheduled liquidity needs rather than company outlook.

Relevance 5/10Novelty 3/10Timing: Filed July 9, covering a July 7 sale under a 10b5-1 plan.

Background

The article is a SEC Form 4 insider transaction disclosure for Ionis Pharmaceuticals.

Company-level read

Ticker impact

$IONSNeutralHigh confidence
Context

Ionis Pharmaceuticals disclosed an EVP Chief Scientific Officer open-market sale of 15,000 shares at $85.4620 on a 10b5-1 plan.

Expected impact

Likely limited near-term impact; traders may view it as routine 10b5-1 selling rather than a signal.

Evidence & confidence

The filing is a Form 4 for an indirect holdings sale under a pre-arranged Rule 10b5-1 plan, with no accompanying operational or guidance change.

Market effects

Sector

No clear read-across to the biotech sector from a single routine insider sale.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Even with a 10b5-1 plan, some traders may interpret repeated insider selling as a mild bearish signal about near-term risk.

Key entities

  • issuer
    IONIS PHARMACEUTICALS INC

    Company whose insider transaction was reported on Form 4.

  • insider
    BENNETT C FRANK

    EVP, Chief Scientific Officer who sold shares under a Rule 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

IONS insider trading history →

Related articles

SEP 25
$IONSHighAI 8/10

Ionis Pharmaceuticals (IONS) Posted Two Positive Phase 3 Trial Readouts

Ionis Pharmaceuticals (IONS) reported positive Phase 3 trial results for two RNA-targeted drugs: sefaxersen, partnered with Roche, met its primary endpoint in IgA nephropathy, and ulefnersen, developed with Otsuka, achieved its main goal in FUS-ALS. These results could expand Ionis's market share and revenue, but pricing and regulatory risks remain.

simplywall.st3 min
SEP 23
$IONSHighAI 8/10

Ionis Phase 3 sefaxersen trial meets IgAN endpoint

Ionis Pharmaceuticals announced that its Phase 3 IMAgINATION trial for sefaxersen met its primary endpoint, showing a statistically significant and clinically meaningful reduction in urine protein at week 37 compared to placebo. The trial, conducted with Roche, remains blinded for a week-105 comparison of kidney function. Ionis may receive milestones and royalties if sefaxersen advances and sells.

mugglehead.com2 min
SEP 23
$IONSMedAI 8/10

Ionis Pharmaceuticals stock hits 52-week low at $44.20

Ionis Pharmaceuticals (IONS) stock hit a 52-week low of $44.20, trading at $44.24 with a $7.39B market cap. The stock has fallen 30.81% over the past year and 42% year-to-date. Analysts have mixed views, with price targets ranging from $54 to $105. Recent clinical trial results showed positive outcomes for Ulefnersen in FUS-ALS, but some analysts lowered price targets due to concerns about drug launches and trial results.

investing.com2 min
SEP 23
$IONSMedAI 8/10

BMO reiterates Ionis Pharmaceuticals stock rating on ALS drug data

BMO Capital reiterated a Market Perform rating and $54 price target for Ionis Pharmaceuticals (IONS) after positive ALS drug trial results. The stock is near its 52-week low, down 42% YTD. The study met primary endpoints, showing functional improvement and survival benefits. Analysts have mixed outlooks, with some lowering price targets due to recent setbacks.

investing.com2 min
SEP 23
$IONSMedAI 8/10

Roche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nod

Roche and Ionis Pharmaceuticals reported positive Phase 3 trial results for sefaxersen, their RNA therapy for kidney disease, meeting the primary endpoint of reducing proteinuria. The drug showed a statistically significant improvement in urine protein-to-creatinine ratio compared to placebo, suggesting potential for accelerated FDA approval. Ionis' CEO indicated a regulatory filing would follow soon.

biospace.com2 min